Unknown PHASE4 INTERVENTIONAL 2-arm NCT02401971

Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer (ITAGC)

Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial

Sponsor: Henan Provincial People's Hospital

Conditions Gastric Cancer

Interventions CPT-11 Thalidomide

Updated 7 times since 2017 Last updated: Mar 27, 2015 Started: Aug 31, 2014 Primary completion: Aug 31, 2016 Completion: Aug 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Gastric Cancer and is currently ongoing. Henan Provincial People's Hospital leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Apr 2020 — Jan 2021 [monthly]

Unknown Status PHASE4
Sep 2018 — Apr 2020 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henan Provincial People's Hospital
Second Affiliated Hospital of Zhengzhou University
The First Affiliated Hospital of Henan University of Science and Technology
The First Affiliated Hospital of Zhengzhou University
Wang Jufeng

Data source: Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China